These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

177 related items for PubMed ID: 2055813

  • 1. Pharmacokinetics of parenteral imipenem/cilastatin in patients on continuous ambulatory peritoneal dialysis.
    Chan CY, Lai KN, Lam AW, Li PK, Chung WW, French GL.
    J Antimicrob Chemother; 1991 Feb; 27(2):225-32. PubMed ID: 2055813
    [Abstract] [Full Text] [Related]

  • 2. [Clinical pharmacokinetics of an imipenem-cilastatin combination].
    Singlas E.
    Presse Med; 1990 Apr 04; 19(13):598-605. PubMed ID: 2139939
    [Abstract] [Full Text] [Related]

  • 3. Pharmacokinetics of intravenous imipenem/cilastatin during intermittent haemofiltration.
    Alarabi AA, Cars O, Danielson BG, Salmonson T, Wikström B.
    J Antimicrob Chemother; 1990 Jul 04; 26(1):91-8. PubMed ID: 2211452
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics of meropenem compared to imipenem-cilastatin in young, healthy males.
    Nilsson-Ehle I, Hutchison M, Haworth SJ, Norrby SR.
    Eur J Clin Microbiol Infect Dis; 1991 Feb 04; 10(2):85-8. PubMed ID: 1864280
    [Abstract] [Full Text] [Related]

  • 5. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis.
    Somani P, Freimer EH, Gross ML, Higgins JT.
    Antimicrob Agents Chemother; 1988 Apr 04; 32(4):530-4. PubMed ID: 3377464
    [Abstract] [Full Text] [Related]

  • 6. Pharmacokinetic profiles of intravenous imipenem/cilastatin during slow hemodialysis in critically ill patients.
    Kihara M, Ikeda Y, Shibata K, Masumori S, Ebira H, Shiratori K, Ueda S, Takagi N, Umemura S, Shionoiri H.
    Clin Nephrol; 1994 Sep 04; 42(3):193-7. PubMed ID: 7994939
    [Abstract] [Full Text] [Related]

  • 7. Imipenem/cilastatin sodium in the treatment of continuous ambulatory peritoneal dialysis-associated peritonitis.
    Lui SF, Cheng AB, Leung CB, Wong KC, Li PK, Lai KN.
    Am J Nephrol; 1994 Sep 04; 14(3):182-6. PubMed ID: 7977477
    [Abstract] [Full Text] [Related]

  • 8. Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failure.
    Konishi K, Suzuki H, Saruta T, Hayashi M, Deguchi N, Tazaki H, Hisaka A.
    Antimicrob Agents Chemother; 1991 Aug 04; 35(8):1616-20. PubMed ID: 1929334
    [Abstract] [Full Text] [Related]

  • 9. Bile levels of imipenem in patients with T-drain following the administration of imipenem/cilastatin.
    Mayer M, Tophof C, Opferkuch W.
    Infection; 1988 Aug 04; 16(4):225-8. PubMed ID: 3182087
    [Abstract] [Full Text] [Related]

  • 10. Comparison of 30-min and 3-h infusion regimens for imipenem/cilastatin and for meropenem evaluated by Monte Carlo simulation.
    Lee LS, Kinzig-Schippers M, Nafziger AN, Ma L, Sörgel F, Jones RN, Drusano GL, Bertino JS.
    Diagn Microbiol Infect Dis; 2010 Nov 04; 68(3):251-8. PubMed ID: 20851549
    [Abstract] [Full Text] [Related]

  • 11. Pharmacokinetics of imipenem-cilastatin in critically ill patients undergoing continuous venovenous hemofiltration.
    Tegeder I, Bremer F, Oelkers R, Schobel H, Schüttler J, Brune K, Geisslinger G.
    Antimicrob Agents Chemother; 1997 Dec 04; 41(12):2640-5. PubMed ID: 9420033
    [Abstract] [Full Text] [Related]

  • 12. Steady-state pharmacokinetics of intramuscular imipenem-cilastatin in elderly patients with various degrees of renal function.
    Pietroski NA, Graziani AL, Lawson LA, Bland JA, Rogers JD, MacGregor RR.
    Antimicrob Agents Chemother; 1991 May 04; 35(5):972-5. PubMed ID: 1854179
    [Abstract] [Full Text] [Related]

  • 13. Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patients.
    Keller E, Fecht H, Böhler J, Schollmeyer P.
    Nephrol Dial Transplant; 1989 May 04; 4(7):640-5. PubMed ID: 2510062
    [Abstract] [Full Text] [Related]

  • 14. Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD).
    Vos MC, Vincent HH, Yzerman EP.
    Intensive Care Med; 1992 May 04; 18(5):282-5. PubMed ID: 1527259
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of imipenem/cilastatin in neutropenic patients with haematological malignancies.
    Janmohamed RM, Leyland MJ, Kelly J, Farrell I.
    J Antimicrob Chemother; 1990 Mar 04; 25(3):407-12. PubMed ID: 2338419
    [Abstract] [Full Text] [Related]

  • 16. [Study of the intraperitoneal penetration of imipenem/cilastatin in acute peritonitis with perforation].
    Pezé P, Mounier M, Cevallos R, Denis F.
    Pathol Biol (Paris); 1990 Jun 04; 38(5 ( Pt 2)):504-7. PubMed ID: 2385446
    [Abstract] [Full Text] [Related]

  • 17. Imipenem/cilastatin: evolution of the sustained-release intramuscular formulation.
    Kahan FM, Rogers JD.
    Chemotherapy; 1991 Jun 04; 37 Suppl 2():21-5. PubMed ID: 1879183
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically ill.
    Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y.
    ASAIO J; 1997 Jun 04; 43(1):84-8. PubMed ID: 9116359
    [Abstract] [Full Text] [Related]

  • 19. Cefazolin plus ceftazidime versus imipenem/cilastatin monotherapy for treatment of CAPD peritonitis--a randomized controlled trial.
    Leung CB, Szeto CC, Chow KM, Kwan BC, Wang AY, Lui SF, Li PK.
    Perit Dial Int; 2004 Jun 04; 24(5):440-6. PubMed ID: 15490983
    [Abstract] [Full Text] [Related]

  • 20. Pharmacokinetics of Imipenem/Cilastatin Burn Intensive Care Unit Patients Undergoing High-Dose Continuous Venovenous Hemofiltration.
    Boucher BA, Hudson JQ, Hill DM, Swanson JM, Wood GC, Laizure SC, Arnold-Ross A, Hu ZY, Hickerson WL.
    Pharmacotherapy; 2016 Dec 04; 36(12):1229-1237. PubMed ID: 27862103
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.